Padmanee Sharma
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 158
- Cancer Immunotherapy and Biomarkers 135
- CAR-T cell therapy research 53
- Immunology 108
- Immunotherapy and Immune Responses 69
- Immune Cell Function and Interaction 34
- Immune cells in cancer 20
- Co-authors
- James Patrick Allison (54 shared papers)Jennifer Ann Wargo (12 shared papers)Antoni Ribas (3 shared papers)Siwen Hu‐Lieskovan (1 shared paper)Sumit Kumar Subudhi (21 shared papers)Beth Ann Helmink (2 shared papers)Golnaz Morad (2 shared papers)Jianjun Gao (17 shared papers)
- Journals
- Journal for ImmunoTherapy of Cancer (21 papers)Clinical Cancer Research (17 papers)Cancer Immunology Research (13 papers)Blood (13 papers)Nature Communications (11 papers)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Padmanee Sharma
240 papers receiving 59.2k citations
Padmanee Sharma's Hit Papers
Peers
Comparison fields: 5 of 170
- Oncology 34.6k
- Immunology 20.6k
- Cancer Research 5.4k
- Pulmonary and Respiratory Medicine 11.3k
- Biological Psychiatry 479
Countries citing papers authored by Padmanee Sharma
This map shows the geographic impact of Padmanee Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Padmanee Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Padmanee Sharma more than expected).
Fields of papers citing papers by Padmanee Sharma
This network shows the impact of papers produced by Padmanee Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Padmanee Sharma. The network helps show where Padmanee Sharma may publish in the future.
Co-authors
The 25 scholars most cited alongside Padmanee Sharma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 245 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy Hit paper breakdown → | 2017 | 4325 |
| 3 | The future of immune checkpoint therapy Hit paper breakdown → | 2015 | 4008 |
| 4 | Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Hit paper breakdown → | 2017 | 3810 |
| 5 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 6 | Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival Hit paper breakdown → | 2014 | 2187 |
| 7 | B cells and tertiary lymphoid structures promote immunotherapy response Hit paper breakdown → | 2020 | 2012 |
| 8 | Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential Hit paper breakdown → | 2015 | 1947 |
| 9 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1377 |
| 10 | Hallmarks of response, resistance, and toxicity to immune checkpoint blockade Hit paper breakdown → | 2021 | 1255 |
| 11 | PD-L1 Expression in Triple-Negative Breast Cancer Hit paper breakdown → | 2014 | 1152 |
| 12 | Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade Hit paper breakdown → | 2017 | 1077 |
| 13 | Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy Hit paper breakdown → | 2016 | 1075 |
| 14 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 1067 |
| 15 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Hit paper breakdown → | 2016 | 817 |
| 16 | Immune checkpoint therapy—current perspectives and future directions Hit paper breakdown → | 2023 | 793 |
| 17 | Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Hit paper breakdown → | 2015 | 770 |
| 18 | Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Hit paper breakdown → | 2021 | 716 |
| 19 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance Hit paper breakdown → | 2017 | 701 |
| 20 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Hit paper breakdown → | 2018 | 679 |
About Padmanee Sharma
Padmanee Sharma is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Hematology and Surgery, having authored 245 papers that have together received 60.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (135 papers), Immunotherapy and Immune Responses (69 papers), CAR-T cell therapy research (53 papers), Immune Cell Function and Interaction (34 papers), Bladder and Urothelial Cancer Treatments (26 papers), Immune cells in cancer (20 papers), Renal cell carcinoma treatment (20 papers) and Acute Myeloid Leukemia Research (14 papers). The work is most often cited by research in Oncology (34.6k citations), Immunology (20.6k citations), Cancer Research (5.4k citations), Pulmonary and Respiratory Medicine (11.3k citations) and Biological Psychiatry (479 citations). Padmanee Sharma has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include James Patrick Allison, Jennifer Ann Wargo, Antoni Ribas, Siwen Hu‐Lieskovan, Sumit Kumar Subudhi, Beth Ann Helmink, Golnaz Morad, Jianjun Gao, Sangeeta Goswami and Jedd D. Wolchok. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Cancer Immunology Research, Blood and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.